Soligenix Management

Management Kriterienprüfungen 4/4

Soligenix CEO ist Christopher Schaber , ernannt in Aug 2006, hat eine Amtszeit von 18.33 Jahren. Die jährliche Gesamtvergütung beträgt $700.49K , bestehend aus 74.2% Gehalt und 25.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.015% der Aktien des Unternehmens, im Wert von $1.12K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 10.5 Jahre bzw. 15.5 Jahre.

Wichtige Informationen

Christopher Schaber

Geschäftsführender

US$700.5k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	74.2%
Amtszeit als Geschäftsführer	18.3yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	10.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	15.5yrs

Jüngste Management Updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Christopher Schaber im Vergleich zu den Einnahmen von Soligenix verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$700k	US$519k	-US$6m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$619k	US$453k	-US$9m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$674k	US$444k	-US$7m

Vergütung im Vergleich zum Markt: ChristopherDie Gesamtvergütung ($USD700.49K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD653.16K).

Entschädigung vs. Einkommen: ChristopherDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Christopher Schaber (58 yo)

18.3yrs

Amtszeit

US$700,485

Vergütung

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christopher Schaber	Chairman of the Board of Directors	18.3yrs	US$700.49k	0.015% $ 1.1k
Jonathan Guarino	Senior VP	5.3yrs	US$354.69k	0.0018% $ 135.5
Oreola Donini	Senior VP & Chief Scientific Officer	10yrs	US$387.59k	0% $ 0
Richard Straube	Senior VP & Chief Medical Officer	10.9yrs	US$249.94k	0.0014% $ 99.9

10.5yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: SNGXDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (10.5 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christopher Schaber	Chairman of the Board of Directors	18.3yrs	US$700.49k	0.015% $ 1.1k
Jerome Zeldis	Independent Director	13.5yrs	US$72.50k	0.0038% $ 283.5
Gregory Lapointe	Independent Director	15.8yrs	US$77.50k	0.0012% $ 91.8
Robert Rubin	Independent Director	15.2yrs	US$80.00k	0.00076% $ 56.3
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	keine Daten	keine Daten
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	keine Daten	keine Daten
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	keine Daten	keine Daten
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	keine Daten	keine Daten
Gary Wood	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	keine Daten	keine Daten

15.5yrs

Durchschnittliche Betriebszugehörigkeit

69.5yo

Durchschnittliches Alter

Erfahrener Vorstand: SNGXDie Vorstandsmitglieder sind sehr erfahren ( 15.5 ).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2024/12/23 17:38
Aktienkurs zum Tagesende	2024/12/23 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Soligenix, Inc. wird von 7 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Robert LeBoyer	Aegis Capital Corporation
James Molloy	Alliance Global Partners
Jonathan Aschoff	Brean Capital

Soligenix Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Recent updates

Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 13% to US$35.00

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Consensus EPS estimates upgraded to US$0.63 loss

Price target increased by 7.7% to US$3.50

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Consensus revenue estimates decrease by 11%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

New major risk - Share price stability

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 35% to US$3.25

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Consensus revenue estimates increase by 13%

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

No longer forecast to breakeven

Consensus revenue estimates decrease by 76%, EPS upgraded

No longer forecast to breakeven

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

Price target decreased to US$3.88